According to this study:
Treatment with Vyzulta reduced IOP by an average of 29.9% and 31.8% in patients with POAG and PXG, respectively, and improved retinal vessel density. Therefore, Vyzulta likely increases macular microcirculation, possibly via nitric oxide, independent of its IOP-reducing effect.
